Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Concert Pharmaceuticals presents phase I preliminary data for CTP-692

June 6, 2019

Anxiolytic effect for JNJ-61393215 seen in humans

June 5, 2019

FDA accepts Prevail's IND for phase I/II study of PR-001 for Parkinson's disease with GBA1 mutation

June 5, 2019

FDA approves Emgality for episodic cluster headache

June 5, 2019

Oligomerix continues NIH-funded work on tau oligomer inhibitor

June 4, 2019

Polish researchers identify 5-HT6 receptor antagonists

June 4, 2019

Kissei Pharmaceutical describes CGRP receptor antagonists

June 4, 2019

Fragile X quick-ish fix?

June 3, 2019

Patient enrollment ongoing in phase I study of BIIB-100

June 3, 2019

Promising phase II efficacy data presented for NRX-101

May 31, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Taiwan biotech looks outward in next phase of growth
BioWorld
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to...